Acadian Asset Management LLC Iveric Bio, Inc. Transaction History

Acadian Asset Management LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $219,534 - $304,979	12,734 New	12,734 $271,000
Q1 2021 May 11, 2021	SELL	$5.08 - $6.89 $289,458 - $392,592	-56,980 Closed	0 $0
Q4 2020 Feb 11, 2021	SELL	$5.65 - $7.66 $2.57 Million - $3.48 Million	-454,745 Reduced 88.87%	56,980 $394,000
Q3 2020 Nov 09, 2020	SELL	$4.01 - $6.29 $1.75 Million - $2.75 Million	-436,567 Reduced 46.04%	511,725 $2.89 Million
Q2 2020 Aug 12, 2020	BUY	$3.06 - $6.6 $119,082 - $256,845	38,916 Added 4.28%	948,292 $4.84 Million

Q1 2020 May 11, 2020	BUY	$2.83 - $8.44 $56,124 - $167,382	19,832 Added 2.23%	909,376 $3.13 Million
Q4 2019 Feb 06, 2020	SELL	$0.93 - $8.58 $326,228 - $3.01 Million	-350,783 Reduced 28.28%	889,544 $7.63 Million
Q3 2019 Nov 07, 2019	SELL	$1.09 - $1.29 $21,885 - $25,900	-20,078 Reduced 1.59%	1,240,327 $1.39 Million
Q2 2019 Aug 08, 2019	BUY	$1.21 - $1.48 $1.53 Million - $1.87 Million	1,260,405 New	1,260,405 $1.64 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Acadian Asset Management LLC with notifications on news.